scispace - formally typeset
G

Gabriela Kramer-Marek

Researcher at Institute of Cancer Research

Publications -  66
Citations -  2078

Gabriela Kramer-Marek is an academic researcher from Institute of Cancer Research. The author has contributed to research in topics: In vivo & Affibody molecule. The author has an hindex of 25, co-authored 57 publications receiving 1771 citations. Previous affiliations of Gabriela Kramer-Marek include National Institutes of Health & Indiana University – Purdue University Indianapolis.

Papers
More filters
Journal ArticleDOI

Diagnostic and Therapeutic Biomarkers in Glioblastoma: Current Status and Future Perspectives.

Wojciech Szopa, +3 more
- 20 Feb 2017 - 
TL;DR: The exciting progress towards elucidating the potential of current and novel GBM biomarkers is reviewed and their implications for clinical practice are discussed.
Journal ArticleDOI

Affibody Molecules for In vivo Characterization of HER2-Positive Tumors by Near-Infrared Imaging

Sang Bong Lee, +7 more
- 15 Jun 2008 - 
TL;DR: The results suggest that Affibody-Alexa Fluor conjugates may be used as a specific NIR probe for the noninvasive semiquantitative imaging of HER2 expression in vivo.
Journal ArticleDOI

[18F]FBEM-ZHER2:342-Affibody molecule - a new molecular tracer for in vivo monitoring of HER2 expression by positron emission tomography

Gabriela Kramer-Marek, +5 more
- 01 May 2008 - 
TL;DR: The results suggest that the [18F]FBEM-ZHER2:342 radioconjugate can be used to assess HER2 expression in vivo and lowered the accumulation of radioactivity in HER2-positive tumors to the levels observed in Her2-negative ones.
Journal ArticleDOI

Changes in HER2 expression in breast cancer xenografts after therapy can be quantified using PET and (18)F-labeled affibody molecules.

Gabriela Kramer-Marek, +2 more
- 01 Jul 2009 - 
TL;DR: The results suggest that the described 18F-FBEM–ZHER2:342 Affibody molecule can be used to assess HER2 expression in vivo by PET and monitor possible changes of receptor expression in response to therapeutic interventions.
Journal ArticleDOI

HER2-specific affibody-conjugated thermosensitive liposomes (Affisomes) for improved delivery of anticancer agents.

Anu Puri, +9 more
- 09 Dec 2008 - 
TL;DR: Thermosensitive liposomes present promising, novel drug-delivery candidates for breast cancer targeting as well as nontargeted SUV candidates, and Affisomes, when stored at room temperature, retained > 90% entrapped calcein up to 7 days.